- Home
- ANEB vs ACXP Comparison
ANEB vs ACXP Comparison
Compare ANEB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ACXP
- Stock Information
- Founded
- ANEB 2020
- ACXP 2017
- Country
- ANEB United States
- ACXP United States
- Employees
- ANEB N/A
- ACXP N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- ACXP Health Care
- Exchange
- ANEB Nasdaq
- ACXP Nasdaq
- Market Cap
- ANEB 111.8M
- ACXP 6.8M
- IPO Year
- ANEB 2021
- ACXP 2021
- Fundamental
- Price
- ANEB $2.56
- ACXP $6.80
- Analyst Decision
- ANEB Buy
- ACXP Strong Buy
- Analyst Count
- ANEB 2
- ACXP 3
- Target Price
- ANEB $8.00
- ACXP $143.67
- AVG Volume (30 Days)
- ANEB 29.2K
- ACXP 1.6M
- Earning Date
- ANEB 11-12-2025
- ACXP 11-12-2025
- Dividend Yield
- ANEB N/A
- ACXP N/A
- EPS Growth
- ANEB N/A
- ACXP N/A
- EPS
- ANEB N/A
- ACXP N/A
- Revenue
- ANEB N/A
- ACXP N/A
- Revenue This Year
- ANEB N/A
- ACXP N/A
- Revenue Next Year
- ANEB N/A
- ACXP N/A
- P/E Ratio
- ANEB N/A
- ACXP N/A
- Revenue Growth
- ANEB N/A
- ACXP N/A
- 52 Week Low
- ANEB $0.80
- ACXP $3.80
- 52 Week High
- ANEB $3.42
- ACXP $41.00
- Technical
- Relative Strength Index (RSI)
- ANEB 56.80
- ACXP 63.75
- Support Level
- ANEB $2.30
- ACXP $6.75
- Resistance Level
- ANEB $2.74
- ACXP $7.98
- Average True Range (ATR)
- ANEB 0.14
- ACXP 0.70
- MACD
- ANEB 0.03
- ACXP 0.16
- Stochastic Oscillator
- ANEB 65.00
- ACXP 63.93
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.